While pharma companies are embracing the transition to digital, and investing significantly in their new products, only 4% of senior executives agree that their digital product launches are
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.